Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q1 2022 Earnings Presentation
11 slides from Sanara Medtech's earnings presentation, May 1, 2022
Slide 1: Q1 2022 Earnings and Business Update Call
Q1 2022 Earnings and Business Update Call
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Overview: Commentary on Q1 2022
Overview Commentary on Q1 2022 • Financial Update • Highest sales quarter ($7.8 million) in the Company’s history; first quarter with a month in which the Company generated >$3 million in sales • Net loss of $3.2 million for Q1 2022 • Net loss compared to Q1 2021 impacted by increased SG&A (+$4.0 mi
Slide 4: Surgical Products
Surgical Products Surgical Overview • 31 field sales managers (8 territory sales managers (“TSM”)) • CellerateRX Surgical sold in 562 hospitals/ASCs in the trailing twelve months • CellerateRX Surgical sold in hospitals/ASCs across 26 states(1) in the TTM • CellerateRX Surgical approved to be sold i
Slide 5: WounDerm Overview
WounDerm Overview Evidence Based Healing
Slide 6: Comprehensive Wound & Skin Solution for All Care Settings
Comprehensive Wound & Skin Solution for All Care Settings Sanara plans to deliver a comprehensive wound care ecosystem targeting the entire continuum of care All Care Settings Acute Post - Acute Physician Inpatient OR ASC LTACH Physician Clinics and Home SNF LTC Office Hospital Office WCC Health Con
Slide 7: Sanara MedTech: A Comprehensive Solution for Wound Care
Sanara MedTech A Comprehensive Solution for Wound Care Sanara is a provider of products and technologies for surgical and chronic wounds dedicated to improving patient outcomes. The components of Sanara’s offering are complementary and promote improved outcomes. Sanara Solution Disruption Compared t
Slide 8: Sanara MedTech Portfolio
Sanara MedTech Portfolio Innovative, Comprehensive, Complementary Diagnostics/Treatment Algorithms EMR and Mobile App Virtual Consult • Novel and disruptive approach to unmet need in • Provider to patient interface • MGroup Strategies the care of skin and chronic wounds • Capabilities include: • Wou
Slide 9: Financial Overview
Financial Overview Evidence Based Healing
Slide 10: Q1 2022 Financial Highlights
Q1 2022 Financial Highlights Overview • Revenue • For the three months ended March 31, 2022, revenues totaled $7.8 million compared to revenues of $5.0 million for the three months ended March 31, 2021, representing a 56% increase from the prior year period. • The higher revenues in 2022 were primar
Slide 11: Questions
u Questions Evidence Based Healing